Atossa ends FY2023 with $88.5M cash; two Phase 2 studies fully enrolled, data due H2 2024

ATOSSA THERAPEUTICS, INC.

Cash and equivalents $88.5M as of Dec 31, 2023; no debt outstanding.
Operating expenses $31.4M in 2023, up $3.7M from $27.7M in 2022.
Phase 2 Karisma-Endoxifen (breast density) fully enrolled Nov 2023; top-line data expected H2 2024.
Phase 2 I-SPY 2 (neoadjuvant breast cancer) fully enrolled Feb 2024; data expected H2 2024.
First patient dosed in Phase 2 RECAST DCIS study; EVANGELINE data at AACR April 9, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the forth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-039286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.